Plain-English translation of NCT07563881 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called can help reduce seizures in adults who have focal epilepsy (seizures that start in one specific area of the brain). About 333 adults will receive either the medication at a high dose, the medication at a medium dose, or a placebo (a pill with no active ingredient), and researchers will track how well it works and whether it's safe.
Focal epilepsy can be difficult to control with current medications, and some people continue to have breakthrough seizures even while taking multiple antiseizure drugs. This trial is testing whether this new treatment might offer another option to help people gain better seizure control.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the high-dose medication, medium-dose medication, or placebo — all taken as daily tablets by mouth. Neither you nor the researchers will know which group you're in during the main study period. You'll attend regular visits to report how many seizures you've had (using your e-diary) and to check for any side effects. After the main treatment period ends, you can choose to continue in a long-term safety study or enter an 8-week follow-up period.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Rapport Therapeutics Inc.
Enrollment target
~333 participants
Started
May 2026
Primary completion
July 2029
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rapport Medical
Rapport Therapeutics Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.